News
- Author:
- Ted Bosworth
Publish date: December 18, 2024
“Unlike psoriasis, which we can treat really well by inhibiting a single pathway target, HS is just not that simple,” James G. Krueger, M, PhD, sai...
News
- Author:
- Ted Bosworth
Publish date: December 16, 2024
Technologies such as electrical impedance spectroscopy, optical coherence tomography, and reflectance confocal microscopy have immediate utility fo...
News
- Author:
- Ted Bosworth
Publish date: December 16, 2024
"We as a specialty make and repair more wounds than any other specialty," says Robert S. Kirsner, MD, PhD.
News
- Author:
- Ted Bosworth
Publish date: November 15, 2024
Colchicine is not protective against major CV events after an acute MI, according to a trial of more than 7000 patients.
News
- Author:
- Ted Bosworth
Publish date: October 25, 2024
Experts outlined viable remaining options for treating multi-refractory myeloma, following immunotherapy.
News
- Author:
- Ted Bosworth
Publish date: October 25, 2024
Fiercely debating on best strategies for treating advanced lymphoma, specialists could not reach consensus.
News
- Author:
- Ted Bosworth
Publish date: October 25, 2024
A specialist applies a novel, nuanced approach to Waldenström macroglobulinemia, based on mutational status.
News
- Author:
- Ted Bosworth
Publish date: October 18, 2024
At 16 weeks, all povorcitinib doses were superior to placebo in achieving at least a 4-point reduction on the Itch Numerical Rating Scale and the I...
News
- Author:
- Ted Bosworth
Publish date: October 18, 2024
“Over the whole follow-up, 90% had no need for topical corticosteroids or any other rescue therapy,” reported Diamant Thaçi, MD, PhD.
News
- Author:
- Ted Bosworth
Publish date: October 18, 2024
The slow progress to identify treatments for FFA is illustrated by the fact that only one other double-blind and randomized trial has ever been con...
News
- Author:
- Ted Bosworth
Publish date: October 18, 2024
A discovery that could lead to personalizing therapies, the data identified “distinct systemic biomarker profiles,” Ester Del Duca, MD, said.
News
- Author:
- Ted Bosworth
Publish date: October 18, 2024
Entry criteria for the study included Hurley stage I or II HS with no draining tunnels. Hurley stage III patients were not eligible.
News
- Author:
- Ted Bosworth
Publish date: October 3, 2024
GFAP might soon join serum neurofilament light chain (sNFl) levels for predicting disability, but each has unique features and they appear to provi...
News
- Author:
- Ted Bosworth
Publish date: September 27, 2024
The Scars of Life project was designed to analyze how the age of AD onset affects the severity of symptoms and quality of life.
News
- Author:
- Ted Bosworth
Publish date: September 25, 2024
Overall, there is a sense of progress in ALS. The hope is that clinical research is reaching a tipping point where targeted treatments may offer ho...
